St. Jude Children's Research Hospital This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Scientists trace genomic evolution of high-risk leukemia
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse. (Jinghui Zhang, PhD, and Charles G. Mullighan, MBBS(Hons), MSc, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
Measuring treatment response proves to be a powerful tool for guiding leukemia treatment
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 19, 2015 Category: Pediatrics Source Type: news
St. Jude Children’s Research Hospital appoints new chair of Department of Radiation Oncology
Thomas Merchant, D.O., Ph.D., to oversee radiotherapy programs for the treatment of childhood cancer. (Thomas Merchant, DO, PhD) (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - March 17, 2015 Category: Pediatrics Source Type: news